DexCom, Inc.: Beat — EPS $0.73, Revenue $1.34B
Earnings BeatQ3 2026 · After-market
Did DexCom, Inc. (DXCM) beat earnings today?
Yes, DexCom, Inc. (DXCM) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+8.96% surprise
$0.73Actual
Expected: $0.67
vs. year ago +19.7%
Total Revenue+1.09% surprise
$1.34BActual
Expected: $1.33B
vs. year ago +11.0%
Released Oct 29 · 4:03 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $1.34B | $1.21B | +11.0% |
| Revenue detail — reported lines | |||
| └─Distributor | $1.15B | $1.03B | +11.9% |
| └─Direct | $196.50M | $183.30M | +7.2% |
| └─United States | $969.80M | $851.90M | +14.0% |
| └─International | $374.70M | $357.40M | +5.0% |
| GAAP Basic EPS | $0.73 | $0.73 | +0.0% |
| GAAP Diluted EPS | $0.72 | $0.70 | +2.9% |
| Non-GAAP Diluted EPS | $0.73 | $0.61 | +19.7% |
| Net Income | $275.10M | $283.80M | -3.1% |
| Non-GAAP Net Income | $275.00M | $242.50M | +13.4% |
Financial Outlook / Guidance
| Metric | Next Quarter Outlook | FY 2026 Outlook |
|---|---|---|
| Revenue | — | $5.20-$5.25B (approximately 12-13% growth) |
| Non-GAAP Gross Profit Margin | — | approximately 64% |
| Non-GAAP Operating Margin | — | approximately 24% |
| Adjusted EBITDA Margin | — | approximately 32% |
Business Highlights
- ➤Published the CONNECT randomized clinical trial in *The New England Journal of Medicine*.
- ➤Launched the fully redesigned Stelo experience with enhanced glucose insights.
- ➤Added simplified meal logging and more detailed nutritional information to Stelo.
- ➤Advanced the U.S. rollout of the Dexcom G7 15 Day System.
- ➤Secured the first two international regulatory clearances for G7 15 Day.
- ➤Positioned the global user base transition to the extended-wear platform.
- ➤Authorized up to $1.0B in share repurchases.
- ➤Continued expanding production capacity and exploring new market opportunities.
Management Commentary
Jake Leach, President and CEO
“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives. This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”